We are a neuroscience company forging a new direction to reduce the enormous burden of diseases that impact the nervous system. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.

Nan Fung Life Sciences

Engrail Therapeutics

At Engrail, our purpose is to deliver transformational therapies that improve the lives of patients with devastating neuropsychiatric and neurodevelopmental disorders. Developing new treatments for tough disorders is challenging and expensive. However, we are committed to advancing the development of our pipeline to realize our purpose. 

Today, we are thrilled to announce the close of our oversubscribed $157M Series B Financing Round. Thank you to an A+ syndicate of investors for believing in our team and pipeline of transformational therapies. This includes: F-Prime Capital, Norwest Venture Partners, Forbion, Red Tree Venture Capital, RiverVest Venture Partners, Ysios Capital, Longwood Fund, Eight Roads, Pivotal Life Sciences, and others.

Please see: https://lnkd.in/gw35_KTe


On the rarest of days (February 29), we recognize the courage of all patients with rare diseases, their caregivers, and clinicians. 

Although a rare disease is defined as one with <200,000 patients in the US, collectively over 30 million, or 1 in 10 Americans, are directly impacted. Patients deserve solutions, and we are proud to work towards their development at Engrail.

As we enter the home stretch of 2023, we reflect back on the triumphs, challenges, and new opportunities afforded to us. We are thankful for our great team, investors, trusted advisors, and Industry partners. 

On behalf of Engrail, we wish you and your loved ones a very happy and memorable holiday season!

Please allow us to welcome Dr. Quentin McCubbin as Chief Technical Officer at Engrail!

Quentin will be responsible for leading all aspects of technical operations and drug manufacturing for Engrail. This is particularly exciting as we lay the groundwork for the future ENX-102 phase 3 program as well as first-in-human studies for ENX-104, ENX-105, and the clinical program for ENX-103. 

Quentin brings over 25 years of chemistry, formulation, manufacturing, and leadership experience to Engrail. Recently, Quentin was Chief Manufacturing Officer at Frequency Therapeutics and Head of Technical Operations at Cerevel Therapeutics. Prior to those roles Quentin spent over 15 years in progressive roles at Takeda Pharmaceuticals and its subsidiaries.  

Welcome to the family Quentin!

#neuroscience #pipeline #leadership #cmc #manufacturing #drugdevelopment

Neurocycle Therapeutics GmbH specializes in curating vision data to improve machine learning models.

Neurocycle Therapeutics GmbH

Veezoo offers chat-based data analytics solutions using cutting-edge machine learning and artificial intelligence.

Veezoo

Factacy uncovers valuable insights from data using cutting-edge machine learning and artificial intelligence alternatives.

Factacy

Fundguard offers financial statement analysis, credit risk rating systems, and data analytics solutions using machine learning and semiconductor technology.

Fundguard

AI Acceleration Hardware and Software provides machine learning applications for AI acceleration hardware and software.

AI Acceleration Hardware and Software

Engrail is a technology company that specializes in providing advanced data analytics and machine learning solutions. The company focuses on helping businesses optimize their operations, enhance decision-making, and improve overall performance through the use of cutting-edge AI-driven platforms.

Engrail

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	May 7, 2024 7:57 PM	636e18bf
public peers	general	May 7, 2024 7:57 PM	2ca7ec2c
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 7, 2024 7:57 PM	8e496573
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	411472c0
crunchbase profile	general
li profile	general	May 7, 2024 7:57 PM	ae836c54
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 7, 2024 7:57 PM	4700d6f0
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ENGRAIL

Engrail